Regeneron ends eye disease study due to antibody's safety profile

Trial StartnegativeitepekimabDupixentNegative

AI Analysis

Summary

Regeneron discontinued a uveitis study due to safety concerns with an investigational antibody, adding to the company's recent clinical failures including Phase 3 failures of itepekimab and a melanoma combination regimen.

Clinical Trial Data

Primary Endpoint

Not Met

Outcome Details

Study discontinued due to antibody's safety profile

Importance:7/10

Sentiment:

-0.85

clinical_setbackstudy_discontinuationsafety_concernsophthalmologyuveitis

Related Companies

$REGN

Read the original article

Published by BioSpace on August 18, 2026 11:23 AM

Read Original